Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study
Recommended Citation
O'Leary JG, Fontana RJ, Brown K, Burton JR, Jr., Firpi-Morell R, Muir A, O'Brien C, Rabinovitz M, Reddy KR, Ryan R, Shprecher A, Villadiego S, Prabhakar A, and Brown RS, Jr. Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis c post-orthotopic liver transplant: The randomized galaxy study. Transpl Int 2016; 30(2):196-208.
Document Type
Article
Publication Date
2-1-2017
Publication Title
Transplant international : official journal of the European Society for Organ Transplantation
Abstract
This prospective, randomized, phase 2 study in subjects with recurrent hepatitis C virus (HCV) genotype 1 postorthotopic liver transplant evaluated once-daily simeprevir 150 mg + sofosbuvir 400 mg, with and without ribavirin 1000 mg. Primary endpoint was proportion of subjects with week 12 sustained virologic response (SVR12). Thirty-three subjects without cirrhosis were randomized 1:1:1 into three arms (stratified by genotype/subtype and Q80K): Arm 1, simeprevir + sofosbuvir + ribavirin, 12 weeks; Arm 2, simeprevir + sofosbuvir, 12 weeks; Arm 3, simeprevir + sofosbuvir, 24 weeks; 13 additional subjects (two with cirrhosis, 11 without cirrhosis) entered Arm 3. All 46 subjects received at least one dose of study drug; median age, 60 years; 73.9% male; 80.4% White; 71.7% genotype/subtype 1a [12 (36.4%) of these had Q80K]; median 4.5 years post-transplant. Among randomized subjects, SVR12 was achieved by 81.8% in Arm 1, 100% in Arm 2, and 93.9% in Arm 3; two subjects did not achieve SVR12: one viral relapse (follow-up week 4; Arm 1) and one missing follow-up week 12 data. In total, five subjects had a serious adverse event, considered unrelated to treatment per investigator. Simeprevir exposure was increased relative to the nontransplant setting, but not considered clinically relevant. Simeprevir + sofosbuvir treatment, with or without ribavirin, was efficacious and well tolerated (ClinicalTrials.gov Identifier: NCT02165189).
Medical Subject Headings
Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Patient Reported Outcome Measures; Postoperative Complications; Treatment Outcome
PubMed ID
27896858
Volume
30
Issue
2
First Page
196
Last Page
208
